La chaîne d'options affiche les données clés des options sur actions de Warby Parker à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Warby Parker..

Warby Parker (NYSE:WRBY) Stock, Chaîne d'Options

WARBY PARKER INC-CLASS A

Warby Parker

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Warby Parker Inc

Sypris Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYPR#NASDAQ">SYPR</a>) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported $29.51 million in sales this quarter. This is a 17.00 percent decrease over sales of $35.55 million the same period last year.

Earnings

News

SYPR

Sypris Solutions Q1 EPS $(0.04) Up From $(0.10) YoY, Sales $29.51M Down From $35.55M YoY

Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.61) by 8.2 percent. This is a 26.32 percent increase over losses of $(0.76) per share from the same period last year.

Earnings Beats

ANRO

Alto Neuroscience Q1 EPS $(0.56) Beats $(0.61) Estimate

CoreWeave Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) reported financial results for the first quarter after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45419679/coreweave-reports-strong-first-quarter-2025-results">of the report</a>.
Q1 Earnings: CoreWeave reported first-quarter revenue of $981.63 million, beating analyst <a href="http://benzinga.com/quote/crwv/earnings">estimates</a> of $859.77 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of $1.49 per share.
Total revenue was up 420% on a year-over-year basis. The company said it ended the quarter with a revenue backlog of $25.9 billion. CoreWeave noted that a strategic deal with OpenAI during the quarter added $11.2 billion in revenue backlog. 
The company reported $1.01 billion in operating expenses during the period, up 487% year-over-year, and ended the quarter with $1.28 billion in cash and cash equivalents. 
&#8220;We&#8217;ve delivered an outstanding start to 2025 on multiple fronts. Our strong&nbsp;first quarter&nbsp;financial performance caps a string of milestones including our IPO, our major strategic deal with OpenAI as well as other customer wins, our acquisition of Weights &amp; Biases and many technical achievements,&#8221; said Michael Intrator, co-founder and CEO of CoreWeave.
&#8220;Demand for our platform is robust and accelerating as AI leaders seek the highly performant AI cloud infrastructure required for the most advanced applications. We are scaling as fast as possible to capture that demand. The future runs on CoreWeave.&#8221;
CoreWeave executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET. The company noted that it will provide forward guidance on the call.
CoreWeave has operated data centers across the U.S. and&nbsp;Europe since 2017. The company provides access to Nvidia GPUs to large technology and AI-focused companies.&nbsp;CoreWeave made its public debut on the Nasdaq at $40 per share in March.
CRWV Price Action: <a href="http://benzinga.com/quote/crwv">CoreWeave shares</a> were trading at all-time highs heading into Wednesday&#8217;s report, its first as a public company. The stock was up 7.92% at $68.97, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a></li>
</ul>
Photo: Shutterstock.

Guidance

Movers

Tech

CRWV

Nvidia-Backed CoreWeave Reports Q1 Earnings: Revenue Jumps 420%, Backlog Grows To $25.9 Billion Following OpenAI Deal, Shares Hit All-Time Highs

WIIM

CoreWeave shares are trading higher following Q1 financial results.

Inhibrx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) reported quarterly losses of $(2.80) per share which beat the analyst consensus estimate of $(2.84) by 1.41 percent. This is a 51.47 percent increase over losses of $(5.77) per share from the same period last year.

INBX

Inhibrx Q1 EPS $(2.80) Beats $(2.84) Estimate

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $491.00 thousand which missed the analyst consensus estimate of $1.38 million by 64.42 percent. This is a 49.17 percent decrease over sales of $966.00 thousand the same period last year.

Earnings Misses

ARMP

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for FY2026 Adj EPS of $2.75-$3.25 vs $3.41 analyst estimate. sees sales of $12.180 billion-$12.440 billion vs $12.41 billion analyst estimate.

DXC Technology Sees FY2026 Adj EPS $2.75-$3.25 vs $3.41 Est; Sees Sales $12.180B-$12.440B vs $12.41B Est

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for Q1 Adj EPS of $0.55-$0.65 vs $0.77 analyst estimate. sees sales of $3.040 billion-$3.090 billion vs $3.12 billion analyst estimate.

DXC Technology Sees Q1 Adj EPS $0.55-$0.65 vs $0.77 Est; Sees Sales $3.040B-$3.090B vs $3.12B Est

SPACE

General

RKLB

NASA Selects Rocket Lab To Launch Aspera Mission To Study Galaxy Evolution

Okeanis Eco Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECO#NYSE">ECO</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.24 by 50 percent. This is a 70.73 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $80.15 million which beat the analyst consensus estimate of $74.56 million by 7.49 percent. This is a 27.95 percent decrease over sales of $111.23 million the same period last year.

Okeanis Eco Tankers Q1 Adj. EPS $0.36 Beats $0.24 Estimate, Sales $80.15M Beat $74.56M Estimate

CSCO

Cisco Says EPS Guidance Includes Estimated Impact Of Tariffs Based On Current Trade Policy; AI Infrastructure Orders Surpassing Our $1B Target One Quarter Early

GEE Group Q2 Adj. EPS $(0.30), Sales $24.50M Down From $28.05M YoY

Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.

Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate

BNGO

Bionano Genomics shares are trading higher following better-than-expected Q1 reported financial results.

Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.30) by 73.33 percent. This is a 89.87 percent increase over losses of $(0.79) per share from the same period last year.

ELDN

Eledon Pharma Q1 EPS $(0.08) Beats $(0.30) Estimate

Gold miners&#8217; stocks, 2025&#8217;s standout performers, faced a sharp reversal this week as investor appetite for safe havens cooled following the U.S.-China trade truce, raising fresh doubts about the sustainability of<a href="https://www.benzinga.com/topic/gold-miners"> the sector&#8217;s explosive rally.</a>
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)—a widely tracked proxy for gold mining stocks—plunged 9.6% over three sessions, marking its worst three-day performance since April 2022. 
The move was amplified by a 4.4% drop in gold prices, which now sit 9.2% below the all-time high of $3,500 per ounce reached on April 22.
Losses were broad-based within the GDX components. Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), its largest holding, dropped 10% in just three days. Similar losses were recorded in Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) and Agnico Eagle Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>).
The abrupt reversal comes as risk appetite surges globally, diminishing gold's appeal. The May 12 announcement of a 90-day U.S.-China tariff rollback helped lift equities and risk assets, reducing investor hedges in gold.
<h3 class="wp-block-heading">Technical Setups Signal Caution For Gold</h3>
Technical analysts are growing cautious. Bank of America technical analyst, Paul Ciana said the daily gold chart is showing signs of a potential double top pattern. 
He indicated that a close below $3,200 per ounce would increase the risk of a correction to the $2,900–$3,000 range during the second quarter.
From a fundamental view, David Morrison, senior market analyst at Trade Nation, observed that gold is consolidating around the lower end of its recent range. 
He flagged $3,200 as the first key support level. "It looks as if the path of least resistance may be down for gold, although much now depends on how staunchly the bulls can defend the $3,200 level," he said.
Nikos Tzabouras, senior market analyst at Tradu.com, said the trade truce buoyed market sentiment and reduced near-term demand for havens like gold. 
"Gold remains under pressure, with scope for further declines as risk appetite holds firm," he said, while cautioning that geopolitical uncertainty and central bank buying still support the longer-term case.
<h3 class="wp-block-heading">Seasonality Enters Choppy Phase</h3>
Seasonal trends may also be at play. Historically, gold posts strong gains in the first four months of the year, followed by a choppy stretch between mid-May and mid-July. In that two-month window, bullion has delivered positive returns just 42% of the time over the past decade.
This seasonal lull could compound downside pressure, especially if key support levels fail to hold.
Conclusion: Time to Take Some Chips Off the Table?
While gold miners have delivered strong year-to-date returns – with the GDX ETF up 30% through mid May. 
Yet, the combination of technical weakness, a seasonally soft window, and shifting macro tailwinds suggests a more cautious stance may be warranted in the short term. 
For investors sitting on large gains, this could be an opportune moment to lock in profits—or at least tighten risk controls—while waiting for clearer signals.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45410216/cruises-set-sail-ahead-of-summer-boom-these-3-sp-500-stocks-show-strongest-late-may-seasonality">Cruises Set Sail Ahead Of Summer Boom: These 3 S&amp;P 500 Stocks Show Strongest Late-May Seasonality</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Sector ETFs

Econ #s

Economics

Analyst Ratings

ETFs

Market Vectors ETF Trust Market Vectors Gold Miners

GOLD

Gold Miners Slammed By US-China Trade Truce: Is It Time To Take Profit?

BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.39) by 51.28 percent. This is a 56.3 percent increase over losses of $(1.35) per share from the same period last year.

BCDA

BioCardia Q1 EPS $(0.59) Misses $(0.39) Estimate

Conifer Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) reported quarterly losses of $(0.30) per share. This is a 372.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $10.31 million in sales this quarter. This is a 38.92 percent decrease over sales of $16.89 million the same period last year.

CNFR

Conifer Holdings Q1 Adj. EPS $(0.30) Down From $0.11 YoY, Sales $10.31M Down From $16.89M YoY

BOOT

Boot Barn Holdings shares are trading higher after the company issued Q1 guidance with its midpoint above estimates and announced a $200 million share repurchase program.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Canaan For April Mined 87 Bitcoins

Press Releases

Warby Parker Announces Second Quarter 2024 Results

Warby Parker Announces Participation in the Goldman Sachs 31st Annual Global Retailing Conference

Warby Parker to Announce Third Quarter 2024 Financial Results November 7, 2024

Warby Parker Announces Third Quarter 2024 Results

Warby Parker Announces Participation in the Morgan Stanley Global Consumer & Retail Conference

Warby Parker to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Warby Parker Announces Fourth Quarter and Full Year 2024 Results

Target and Warby Parker Team Up to Bring Stylish, Affordable Eyewear to More Consumers

Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

Warby Parker Announces First Quarter 2025 Results

WRBY

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports

BARK

Build-A-Bear Workshop

Bath & Body Works

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Chewy

Dick's Sporting Goods

Envela

National Vision Holdings, Inc. - Common Stock

National Vision Holdings

Five Below

1-800-FLOWERS.COM, Inc. - Class A Common Stock

1-800-Flowers.com

MarineMax

Leslies

PetMed Express

Park Ha Biological Technology Co., Ltd. - ordinary shares

Park Ha Biological Tech

Sally Beauty Holdings, Inc. (Name to be changed from Sally Holdings, Inc.) Common Stock

Comments

Warby Parker

Warby Parker (WRBY) Options

Loading...

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL